Skip to Content

'
Jeri Kim, M.D.

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Genitourinary (GU) Medical Oncology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1999 UT M.D. Anderson Cancer Center, Houston, TX, Fellowship, Medical Oncology
1996 Baylor College of Medicine, Houston, TX, Internship and Residency, Internal Medicine
1993 University of Southern California, School of Medicine, Los Angeles, CA, MD, Medicine
1988 University of California Los Angeles, Los Angeles, CA, BS, Biochemistry

Board Certifications

2006 Medical Oncology
1996 American Board of Internal Medicine

Experience/Service

Academic Appointments

Regular, Member of The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX, 8/2006-8/2009
Assistant Professor, Department of Genitourinary (GU) Medical Oncology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1999-2005

Administrative Appointments/Responsibilities

Director, Department of Genitourinary (GU) Medical Oncology - Research, Biorepository, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1999-present

Honors and Awards

2005 Participation in AACR Task Force on Prevention Meeting
2004 Incentive for Salary Award
2001-2004 Clinician Investigator Program Career Development Award
2001 Institutional Research Grant Award
1998 Clinical Fellows Research Award
1998 Participation in ASCO/AACR Methods in Clinical Cancer Research, Third Annual Workshop
1997 Clinical Fellows Research Award
1996-1997 Clifton D. Howe Award for Clinical Excellence
1990-1991 Fifth Year Research Scholar, Experimental Cutaneous Injury Due to Hydrofluoric Acid
1987 National Science Foundation Summer Research Fellowship:Organic Chemistry
1984-1988 Dean's Honor List, University of California, Los Angeles

Selected Publications

Peer-Reviewed Original Research Articles
1. Li J, Kim J. Molecular profiles of finasteride effects on prostate carcinogenesis. Cancer Prev Res 2(6):518-24, 6/2009. PMID: 19491289.
2. Blando J, Portis M, Benavides F, Alexander A, Mills G, Conti C, Kim J, Walker CL. PTEN deficiency is fully penetrant for invasive prostate adenocarcinoma in C57B/6 mice. Am J. Pathol 174(5):1869-79, 5/2009. PMID: 19395652.
3. Tsavachidou D, McDonnell TJ, Wen S, Wang X, Vakar-Lopez F, Pisters LL, Pettaway CA, Wood CG, Do KA, Thall PF, Stephens C, Efstathiou E, Taylor R, Menter DG, Troncoso P, Lippman SM, Logothetis CJ, Kim J. Selenium and Vitamin E:Cell Type-and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst 101(5):206-20, 3/2009. PMID: 19244175.
4. Lin SH, Lee YC, Choueiri MB, Wen S, Mathew P, Ye X, Do KA, Kim J, Tu SM, Lu-Lee LY, Logothetis CJ. Soluble ErbB3 levels in bone marrow and plasma in men with prostate cancer. Clin Cancer Res 14(12):3729-36, 6/2008. PMID: 18559590.
5. Jonasch E, Wood C, Tamboli P, Pagliaro LC, Tu SM, Kim J, Srivastava P, Perez C, Isakov L, Tannir N. Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine:clinical finds. Brit J Cancer 98(8):1336-41, 3/2008. PMID: 18362942.
6. Lin SH, Cheng CJ, Lee YC, Ye X, Tsai WW, Kim J, Pasqualini P, Arap W, Navone NM, Tu SM, Hu M, Yu-Lee LY, Logothetis CJ. A 45-kDa ErbB3 secreted by prostate cancer cells promotes bone formation. Oncogene 27(39):5195-203, 2008. PMID: 18490922.
7. Mao S, Daliani DD, Wang X, Thall PF, Do KA, Perez CA, Brown MA, Bouchillon K, Carter CM, Logothetis CJ, Kim J. Employing the treatment-free interval of intermittent androgen ablation to screen candidate prostate cancer therapies. Prostate 67(15):1677-85, 11/2007. PMID: 17879948.
8. Cheng CJ, Ye Xiang-Cang, Vakar-Lopez F, Kim J, Tu SM, Chen DT, Navone NH, Hu MC, Yu-Lee Ly, Lin SH. Bone microenvironment and androgen status modulate subcellular localization of ErbB3 in prostate cancer cells. Mol Cancer Res 5(7):675-84, 7/2007. PMID: 17634423.
9. Subbarayan V, Krieg P, His LC, Kim J, Yang P, Sabichi AL, Llansa N, Mendoza G, Logothetis CJ, Newman RA, Lippman SM, Menter DG. 15-lipoxygenase-2 (15-LOX-2) gene regulation by its product 15-S-hydroxyeicostatetraenoic acid through a negative feed back mechanism that involves peroxisome proliferators-activated receptor gamma. Oncogene 25(44):6015-25, 9/2006. PMID: 16682954.
10. Kelloff GJ, Lippman SM, Dannenberg AJ, Sigman CC, Pearce HL, Reid BJ, Szabo E, Jordan VC, Spitz MR, Mills GB, Papadimitrakopoulou VA, Lotan R, Aggarwal BB, Bresalier RS, Kim J, Arun B, Lu KH, Thomas ME, Rhodes HE, Brewer MA, Follen M, Shin D, Parnes HL, Siegfried J, Evans AA, Blot WJ, Chow WH, Blount PL, Maley CC, Wang KK, Lam S, Lee JJ, Dubinett SM, Engstrom PF, Meyskens FL, O'Shaughnessy JO, Hawk ET, Leven B, Nelson WG, Hong WH. Progress in chemoprevention drug development:the promise of molecular biomarkers for prevention of intraepithelial neoplasia (IEN) and cancer--a plan to move forward. Clin Cancer Res 12(12):3661-97, 6/2006. PMID: 16778094.
11. Tu SM, Kim J, Pagiliaro LC, Vakar-Lopez F, Wong FC, Wen S, General R, Podoloff DA, Lin SH, Logothetis CJ. Strontium-89 combined with chemotherapy does not compromise subsequent tharapy in selected patients with androgen-independent prostate cancer. J Clin Oncol 23(31):7904-10, 11/2005. PMID: 16258090.
12. Lee SH, Nishino M, Mazumdar T, Garcia GE, Galfione M, Lee FL, Lee CL, Liang A, Kim J, Feng L, Eissa T, Lin SH, Yu-Lee LY. Antiangiogenic effect of 16-kDa prolactin involves the inhibition of the IRF-1 pathway that regulates iNOS expression. Cancer Res 65(17):7984-92, 9/2005. PMID: 16140971.
13. Kim J, Yang P, Suraokar M, Sabichi AL, Llansa ND, Mendoza G, Subbarayan V, Logothetis CJ, Newman RA, Lippman SM, Menter DG. Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived products. Cancer Res 65(14):6189-98, 7/2005. PMID: 16024620.
14. Subbarayan V, Xu XC, Kim J, Yang P, Hoque A, Sabichi AL, Llansa N, Mendoza G, Logothetis CJ, Newman RA, Lippman SM, Menter DG. Inverse relationship between 15-lipoxygenase-2 and PPAR-gamma gene expression in normal epithelia compared with tumor epithelia. Neoplasia 7(3):280-93, 3/2005. PMID: 15799828.
15. *Kim J, *Sun P, Troncoso P, Sabichi AL, Babaian RJ, Pisters LL, Pettaway CA, Wood CG, Lam YW, Lippman SM, McDonnell TJ, Lieberman R, Mobley JA, Logothetis C, Ho SM. Changes in serum proteomic patterns by presurgical alpha-tocopherol and L-selenomethionine supplementation in prostate cancer (*co-first authors). Cancer Epidemiol Biomarkers Prev 14:1697-1702, 2005. PMID: 16030104.
16. Subbarayan V, Sabichi AL, Kim J, Llansa N, Logothetis CJ, Lippman SM, Menter DG. Differential peroxisome proliferator-activated receptor-gamma isoform expression and agonist effects in normal and malignant prostate cells. Cancer Epidemiol Biomarkers Prev 13(11 Pt 1):1710-6, 11/2004. PMID: 15533897.
17. Fizazi K, Sikes CR, Kim J, Yang J, Martinez LA, Olive MC, Logothetis CJ, Navone NM. High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer. Anticancer Res 24(5A):2897-903, 9/2004. PMID: 15517894.
18. Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L, Kim J, Adams J, Elliott P, Esseltine D, Petrusich A, Dieringer P, Perez C, Logothetis CJ. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 22(11):2108-21, 6/2004. PMID: 15169797.
19. Vakar-Lopez F, Cheng CJ, Kim J, Shi GG, Troncoso P, Tu SM, Yu-Lee LY, Lin SH. Up-regulation of MDA-BF-1, a secreted isoform of ErbB3, in metastatic prostate cancer cells and activated osteoblasts in bone marrow. J Pathol 203(2):688-95, 6/2004. PMID: 15141384.
20. *Salas TR, *Kim J, Vakar-Lopez F, Sabichi AL, Troncoso P, Jenster G, Kikuchi A, Chen SY, Shemshedini L, Suraokar M, Logothetis CJ, DiGiovanni J, Lippman SM, Menter DG. Glycogen synthase kinase-3 beta is involved in the phosphorylation and suppression of androgen receptor activity.(*co-first authors). J Biol Chem 279(18):19191-200, 4/2004. PMID: 14985354.
21. Mintz PJ, Kim J, Do KA, Wang X, Zinner RG, Cristofanilli M, Arap MA, Hong WK, Troncoso P, Logothetis CJ, Pasqualini R, Arap W. Fingerprinting the circulating repertoire of antibodies from cancer patients. Nat Biotechnol 2(1):57-63, 12/2003. PMID: 12496764.
22. Tu SM, Millikan RE, Pagliaro LC, Daliani D, Papandreou CN, Kim J, Chen DT, Williams DL, Logothetis CJ. Treatment of refractory urothelial carcinoma with alternating paclitaxel, methotrexate, cisplatin (TMP) and 5-fluorouracil, alpha-interferon, cisplatin (FAP). Urol Oncol 21(5):342-8, 9/2003. PMID: 14670540.
23. Galfione M, Luo W, Kim J, Hawke D, Kobayashi R, Clapp C, Yu-Lee LY, Lin SH. Expression and purification of the angiogenesis inhibitor 16-kDa prolactin fragment from insect cells. Protein Expr Purif 28(2):252-8, 4/2003. PMID: 12699689.
24. Kim J, Luo W, Chen DT, Earley K, Tunstead J, Yu-Lee LY, Lin SH. Antitumor activity of the 16-kDa prolactin fragment in prostate cancer. Cancer Res 63(2):386-93, 1/2003. PMID: 12543792.
25. Kim J, Millikan RE, Smith TL, Tu SM, Pagliaro LC, Logothetis CJ. Treating refractory advanced or metastatic urothelial carcinoma with interleukin-2: a phase II study. Urol Oncol 21(1):21-6, 1/2003. PMID: 12684123.
26. Zinner RG, Kim J, Herbst RS. Non-small cell lung cancer clinical trials with trastuzumab: their foundation and preliminary results. Lung Cancer 37(1):17-27, 7/2002. PMID: 12057863.
27. Fizazi K, Prow DM, Do KA, Wang X, Finn L, Kim J, Daliani D, Papandreou CN, Tu SM, Millikan RE, Pagliaro LC, Logothetis CJ, Amato RJ. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours. Br J Cancer 86(10):1555-60, 5/2002. PMID: 12085204.
28. Tu SM, Millikan RE, Mengistu B, Delpassand ES, Amato RJ, Pagilaro LC, Dailani D, Papandreou CN, Smith TL, Kim J, Podoloff DA, Logothetis CJ. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate:a randomized phase II trial. Lancet 357:336-41, 2001. PMID: 11210994.
29. Kim J, Palmer JL, Finn L, Hodges S, Bowes VV, Deftos L, Murphy G, Logothetis C. The pattern of serum markers in patients with androgen-independent adenocarcinoma of the prostate. Urol Oncol 5(3):97-103, 4/2000. PMID: 10765015.
30. Newman RA, Kim J, Newman BM, Bruno R, Bayssas M, Klink-Alaki M, Pazdur R. Phase I trial of intoplicine (RP 60475) administered as a 72 h infusion every 3 weeks in patients with solid tumors. Anticancer Drugs 10(10):889-94, 11/1999. PMID: 10630356.
31. Kim J, Logothetis CJ. Serologic tumor markers, clinical biology, and therapy of prostatic carcinoma. Urol Clin North Am 26(2):281-90, 5/1999. PMID: 10361551.
32. Kim J, Zhi J, Satoh H, Koss-Twardy SG, Passe SM, Patel IH, Pazdur R. Pharmacokinetics of recombinant human interferon-alfa 2a combined with 5-fluorouracil in patients with advanced colorectal carcinoma. Anticancer Drugs 9(8):689-96, 9/1998. PMID: 9823427.
33. Hjelle B, Goade D, Torrez-Martinez N, Lang-Williams M, Kim J, Harris RL, Rawlings JA. Hantavirus pulmonary syndrome, renal insufficiency, and myositis associated with infection by Bayou hantavirus. Clin Infect Dis 23(3):495-500, 9/1996. PMID: 8879771.
34. Kim J, Weibel TJ, Calobrace MB, Foldi JF, Zawacki BE. A standard experimental 'Chemical Burn'. Burns 20(3):200-1, 6/1994. PMID: 8054129.

Invited Articles
1. Zinner RG, Kim J, Herbst RS. Trastuzumab enters non-small cell lung cancer clinical trials. Her2 in Oncol 1(3):2-11, 2000.

Editorials
1. Efstathiou E, Kim J, Logothetis CJ. Informative clinical investigation:a demanding task master. J Clin Oncol. In Press.

Abstracts
1. Davis JW, Troncoso P, Ward J, Babian RJ, Pettaway C, Pisters L, Kuban D, Brown V, Logothetis C, Kim J. Active surveillance for clinically localized prostate cancer in the era of technology:Introduction of a prospective protocol into a high volume tertiary research center. 24th Annual European Association of Urology Congress. Poster Presentation, 2008.
2. Troncoso P, Davis JW, Ward JF, Wang X, Nakanishi H, Babaian RJ, Kim J. Radical prostatectomy findings in patients considered potential candidates for active surveillance. 97th United States and Canadian Academy of Pathology, Abstr #845, Oral Presentation, 2008.
3. Aparicio AM, Lin AM, Araujo JC, Logothetis CJ, Kim J, Pagliaro LC, Tu S, Guo C, Jones D, Thall P, Mathew P. Use of clinical features to select a chemotherapy-responsive variant of aggressive prostate cancer (PC), Abstract 16000. J Clin Oncology 26, 2008.
4. Kim J, Vakar-Lopez F, Wang X, Thall P, Babaian RJ, Pisters LL, Pettaway CA, Wood CG, Lippman SM, Lieberman R, McDonnell T, Sabichi AL, Logothetis CJ, Troncoso P. A Preoperative Model of Clinically Localized Prostate Cancer: The Devil is in the Details. The 13th SPORE Investigators’ Workshop. Oral Presentation:abstr 220, 2005.
5. Tu SM, Kim J, Pagliaro LC, Vakar-Lopez F, Wong FC, Wen S, General R, Podoloff DA, Lin SH, Logothetis CJ. Chronic adverse effects from strontium-89 treatment in patients with androgen-independent prostate cancer and bone metastases. Proceedings of the American Society of Clinical Oncology 41:abstr 4671, 2005.
6. Yang P, Kim J, Chan D, Cartright C, Navone N, Shureiqi I, Newman RA. Defining the role of arachidonate metabolism as an approach for prevention of prostate cancer. 4th American Association of Cancer Research Frontiers in Cancer Prevention Research, Cancer Epidemiol Biomarkers Prev 14 (11 Suppl.):2713S (Abstr. B18), Poster Presentation, 2005.
7. McDonnell TJ, Do KA, Wen S, Troncoso P, Babaian R, Pisters L, Pettaway C, Wood C, Lippman S, Logothetis C, Sabichi A, Xiao L, Zhang L, Kim J. Global gene expression assessment reveal treatment specific and cell type specific responses to selenium and vitamin E in patients with organ-confined prostate cancer. Inter-Prostate SPORE Meeting. Oral Presentation, 2005.
8. Mao S, Daliani D, Wang X, Do KA, Thall PF, Perez CA, Brown MA, Logothetis CJ, Kim J. Phase II randomized, placebo-controlled, double-blind study of IM862 plus a short course of androgen ablation for patients with androgen-dependent prostate cancer who failed local therapies - A platform for new drug screening. Proceedings of the American Society of Clinical Oncology 41:abstr 4684, 2005.
9. Tu S, Kim J, Pagliaro LC, Vakar-Lopez F, Wong FC, Wen S, General R, Podoloff DA, Lin S, Logothetis CJ. Strontium-89 combined with chemotherapy does not compromise subsequent therapy in selected patients with androgen-independent prostate cancer. Skeletal Complications of Malignancy IV. Poster Presentation:abstr 93, 2005.
10. Suraokar M, Kim J, Llansa N, Mendosa G, Logothetis CJ, Lippman SM, Menter DG. Tetracycline-inducible mouse U6 vector for conditional expression of shRNA. Proceedings of the American Association for Cancer Research 46. Poster Presentation:abstr 5442, 2005.
11. Kim J, Vakar-Lopez F, Thall PF, Wang X, Stephens CL, Babaian RJ, Pisters LL, Pettaway CA, Wood CG, Pereira P, Soto C, Menter DG, Lieberman R, McDonnell TJ, Lippman SM, Sabichi AL, Logothetis CJ, Troncoso P. The effects of selenium and vitamin E on apoptosis and proliferation in prostate tissue from a preprostatectomy study in patients with clinically organ-confined prostate cancer. Proceedings of the American Association for Cancer Research 46. Poster Presentation:abstr 1612, 2005.
12. Kim J, Do KA, Wen S, Troncoso P, Babaian RJ, Pisters LL, Pettaway CA, Wood CG, Lippman SM, Logothetis CJ, Sabichi AL, Xiao L, Zhang L, McDonnell TJ. A global assessment of gene expression in prostate cancer cells from patients enrolled in a phase IIA, randomized trial of selenium and vitamin E. The 12th SPORE Investigators' Workshop. Poster Discussion:abstr 107, 2004.
13. Suraokar M, Kim J, Lippman SM, Menter DG. Elucidating the role of selenoproteins in prostate cancer using a novel conditional and inducible lentiviral-based siRNA vector. MD Anderson Trainee Recognition Day & Research Exposition, 2004.
14. Kim J, Yang P, Sabichi AL, Vakar-Lopez F, Llansa N, Mendosa G, Newman RA, Lippman SM, Menter DG. Prostate stromal prostaglandin D2 synthase-derived eicosanoid products suppress prostate cancer cell growth. Proceedings of the American Association for Cancer Research 45. Poster Presentation:abstr 873, 2004.
15. Vakar-Lopez F, Cheng C-J, Kim J, Shi GG, Tunstead JR, Troncoso P, Ruggeri A, Tu S-M, Lin S-H. Up-regulation of soluble ErbB3 in metastatic prostate cancer cells and activated osteoblasts in bone marrow. The 93rd Annual U.S. and Canadian Academy of Pathology Meeting. Poster Presentation:abstr 764, 2004.

Book Chapters
1. Kim J, Logothetis C. A biological framework for the development of therapy in prostate cancer. In: Progress in Anti-Cancer Chemotherapy. Springer-Verlag, 189-201, 2000.

Manuals, Teaching Aids, Other Teaching Publications
1. Kim J. Standard Operations Manual, Genitourinary Medical Oncology Serum Bank, 2000.

Grant & Contract Support

Title: The University of Texas M.D. Anderson SPORE in Prostate Cancer, Specimen Core.
Funding Source: NIH/NCI
Role: Collaborator
Duration: 7/1/2009 - 6/30/2014
 
Title: A Randomized Controlled Trial Evaluating the Tissue Effects of Preoperative Finasteride versus Placebo for Patients with Clincally Organ-Confined Prostate Cancer
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 2007 - 2011
 
Title: An animal model for adverse progression of prostate cancer, The University of Texas M.D. Anderson SPORE in Prostate Cancer
Funding Source: NIH/NCI
Role: Co-Investigator
Duration: 1/12/2006 - 12/31/2007
 
Title: Collaboration between Royal Marsden NHS Trust/Institute of Cancer Research and The University of Texas M.D. Anderson Cancer Center through Establishment of Postdocotral Fellowship, 1-Selenomethionine, alpha-tocopherol, and oxidative stress:their effects on cell death and gene regulation in prostate cells
Funding Source: The Kadoorie Charitable Foundation
Role: Collaborator
Duration: 2003 - 2007
 
Title: Differential gene expression induced by antioxidants, National Cancer Institute
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 2003 - 2007
 
Title: Modulation of the arachidonic acid cascade by l-selenomethionine and alpha-tocopherol in normal and malignant prostate cells, The University of Texas M. D. Anderson SPORE in Prostate Cancer Career Development Award
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 2003 - 2005
 
Title: The University of Texas M.D. Anderson SPORE in Prostate Cancer, Tissue Resource & Pathology Core.
Funding Source: NIH/NCI
Role: Collaborator
Duration: 6/1/2001 - 12/31/2007
 
Title: The University of Texas M.D. Anderson SPORE in Prostate Cancer, Tissue Resource & Pathology Core
Funding Source: NIH/NCI
Role: Co-Investigator
Duration: 2001 - 2007
 
Title: Fingerprinting the circulating pool of tumor-related antibodies in cancer patients: Translation into clinical application
Funding Source: Clinician Investigator Career Development Program
Role: Principal Investigator
Duration: 2001 - 2004
 
Title: A feasibility study of l-selenomethionine and alpha-tocopherol in prostate cancer
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 2000 - 2005
 
Title: Toward Individualized Treatment in Patients with Early Prostate Cancer: Genotoxic Stress Induced by Short-term Intervention of Finasteride Enables Dynamic Molecular Risk Stratification.
Funding Source: The University of Texas M.D. Anderson Cancer Center Kleberg Center, Supplies only.
Role: Principal Investigator

Last updated: 9/24/2009